WO2005023321A2 - Extracellular matrix composite materials, and manufacture and use thereof - Google Patents
Extracellular matrix composite materials, and manufacture and use thereof Download PDFInfo
- Publication number
- WO2005023321A2 WO2005023321A2 PCT/US2004/029016 US2004029016W WO2005023321A2 WO 2005023321 A2 WO2005023321 A2 WO 2005023321A2 US 2004029016 W US2004029016 W US 2004029016W WO 2005023321 A2 WO2005023321 A2 WO 2005023321A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- extracellular matrix
- submucosa
- graft
- sis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
Definitions
- the present invention relates generally to medical graft materials, and in particular to medical graft materials having extracellular matrix materials deposited thereon.
- extracellular matrix materials have been proposed for use in medical grafting, cell culture, and other related applications.
- medical grafts and cell culture materials containing submucosa derived from small intestine, stomach or urinary bladder tissues have been proposed. See, e.g., U.S. Patent Nos. 4,902,508,4,956,178, 5,281,422, 5,554,389, 6,099,567 and 6,206,931.
- the present invention provides a material, desirably a medical graft material, comprising a substantially acellular extracellular matrix composite including a first extracellular matrix material having a surface, and a second, biosynthetically-deposited extracellular matrix material on said surface.
- the second, biosynthetically-deposited extracellular matrix material is non-native to the surface of the first extracellular matrix material, i.e., it is added to the surface of the first extracellular matrix material as opposed to being retained from the source of the first extracellular matrix material.
- the inventive composite material is substantially devoid of both cells and cell components.
- the present invention provides a method for inducing endogenous tissue growth in an animal, including the step of implanting in the animal a medical graft material as described above.
- the present invention also provides a method for culturing cells, which involves culturing the cells on an extracellular matrix composite material as described above.
- the present invention also provides a method for making an extracellular matrix composite, comprising the steps of (a) providing a first extracellular matrix material having a surface; (b) culturing cells in vitro under conditions to secrete extracellular matrix components wherein said components are transferred to said surface to form an extracellular matrix composite comprising said first extracellular matrix material with said extracellular matrix components on said surface; and (c) decellularizing the extracellular matrix composite.
- the present invention provides novel materials useful for medical grafting and cell culture, and methods for making and using them. Additional embodiments as well as features and advantages of the invention will be apparent from the descriptions herein. BRIEF DESCRIPTION OF THE DRAWINGS
- Figure 1 provides a perspective view of a tubular graft prosthesis device of the present invention.
- Figure 2 provides a cross-sectional view of the tubular graft prosthesis device depicted in Figure 1 taken along line 2-2 and viewed in the direction of the arrows.
- Figures 3A-3G depict steps used in the manufacture of a 5-layer tubular prosthesis device of the invention.
- Figure 4. HUVEC grown on SIS form a confluent monolayer more slowly than when grown on glass slides. HUVEC were seeded onto glass slides or untreated SIS at a concentration of 100,000 cells/mm 2 and analyzed by immunofluorescence confocal microscopy to determine the length of time needed for cells to form a confluent monolayer.
- HUVEC are efficiently removed from SIS following "conditioning." Native SIS without cells, SIS with HUVEC grown for 14 days, and SIS with HUVEC grown for 14 days and then removed (conditioned) were stained with Hoechst dye to label cell nuclei and viewed in the fluorescence microscope (A) or analyzed by immunoblotting using antibodies against either of two cellular proteins, ⁇ -catenin or mitochondrial glycosylase (B).
- HUVEC deposit human fibronectin onto the surface of conditioned SIS. Immunoblot analysis of native SIS without cells, SIS with HUVEC grown for 14 days, and SIS with HUVEC grown for 14 days and then removed (conditioned) using an antibody that is specific for human fibronectin and has little or no cross reactivity with porcine fibronectin. Human fibronectin deposited by HUVEC is retained on the conditioned SIS following removal of the cells.
- Fig. 8 Cell attachment assays on native and conditioned SIS. HUVEC were labeled with 35S-methonine overnight and then seeded onto native and conditioned SIS to determine if there was a difference in the relative number of cells that were able to adhere to the two surfaces. There was no statistically significant difference in the relative numbers of HUVEC adhered to native or conditioned SIS at times ranging from 1 to 48 hr after seeding. Fig. 9.
- HUVEC Formation of cell-cell adherens junctions is improved in HUVEC grown on conditioned SIS compared to cells grown on native SIS.
- HUVEC were seeded onto native or conditioned SIS at a concentration of 100,000 cells/cm2 and analyzed by immunofluorescence confocal microscopy 48h after seeding.
- Cells were labeled with a mouse monoclonal antibody against ⁇ -catenin or with mouse monoclonal antibody against phosphotyrosine containing proteins followed by an anti-mouse Ig antibody conjugated to FITC to visualize cell-cell junctions.
- NADPH production is greater at 24 and 96 h after plating in HUVEC grown on conditioned SIS compared to native SIS. Metabolic activity assays that measure the production of NADPH by cells were carried out with native and conditioned SIS onto which 100,000 or 200,000 cells/cm2 were seeded for 1-240 h.
- HUVEC grown on conditioned SIS released significantly less prostacyclin (p ⁇ 0:0001) compared to cells grown on native SIS at both 24 and 48 h time points.
- Adhesion of human platelets is lower on conditioned SIS compared to native SIS.
- Adhesion of resting (A) or thrombin activated (B) human platelets labeled with 51Cr was measured on native SIS and conditioned SIS. Platelet adhesion was significantly reduced by 40.4% when resting platelets were used, and by 29.6% when thrombin-activated activated platelets were used.
- the present invention provides medical grafting materials including extracellular matrix composites, and methods for their manufacture and use.
- acellular means free or essentially free from living cells.
- substantially devoid of cells and cell components means free or essentially free from cells (living or dead) and of cell membranes and other cell remnants.
- An ECM material substantially devoid of cells or cell components is intended to include the ECM material carrying cells or cell components at a level sufficiently low to be non-immunogenic when the material is implanted in a recipient, especially a recipient to which the cells or cell components are xenogenic or allogenic.
- decellularizing in respect of a cell-containing ECM material means that the material is treated to as to remove at least about 70% of the original cells (living or dead). More preferably, at least 90% of the cells will be removed, and most preferably at least 99% of the cells will be removed, in decellularization processes involved in the instant invention.
- Medical grafting devices and methods of the invention employ a first extracellular matrix (ECM) base material.
- ECM extracellular matrix
- Suitable extracellular matrix materials include, for instance, submucosa (including for example small intestinal submucosa, stomach submucosa, urinary bladder submucosa, or uterine submucosa, each of these isolated from juvenile or adult animals), renal capsule membrane, amnion, dura mater, pericardium, serosa, peritoneum or basement membrane materials, including liver basement membrane or epithelial basement membrane materials.
- ECM base materials contain residual bioactive proteins or other ECM components derived from the tissue source of the materials.
- they may contain Fibroblast Growth Factor 2 (basic FGF), vascular endothelial growth factor (VEGF), and Transforming Growth Factor-beta (TFG-beta).
- ECM base materials of the invention may contain additional bioactive components including, for example, one or more of glycosaminoglycans, glycoproteins, proteoglycans, and/or growth factors.
- cells will be cultured in vitro on the ECM material under conditions and for a duration wherein secreted extracellular matrix proteins are deposited upon a portion of or the entire surface of the ECM material.
- the resulting ECM composite material can be isolated by decellularizing the material.
- the deposited ECM proteins may, for example, enhance the functionality of the ECM base material, e.g. by potentially affecting remodeling of the material by cells and/or the thrombogenicity of the material.
- the ECM base material along with seeded cells can be subjected to mechanical, chemical or physical stresses to influence the cell growth and deposition products. Such forces could include but are not limited to mechanically stretching the ECM base material, preferably without tearing it, subjecting the ECM base material to pulsatile forces (e.g.
- Cells to be used to secrete ECM proteins can be applied to the surface of the base ECM supporting structure in any suitable fashion. ⁇ lustratively, the cells can be applied to the base ECM material by allowing gravity to settle the cells onto the base ECM. Positive pressure may also be used to force media through the ECM material, thereby depositing cells onto the ECM surface.
- suitable means for applying the cells to the ECM may include, but not be limited to using negative pressure to draw the cells onto the ECM material; and using chemotactic agents, for example.
- chemotactic agents for example.
- type and source of the cells to be used to deposit ECM components onto the ECM base material a variety of cell types, or combinations of cell types, may be used. These cell types are known to those of ordinary skill in the art, as are appropriate conditions for their culture.
- cell types to produce the ECM proteins for deposition include vascular and other endothelial cells (including microvascular endothelial cells), vascular and other smooth muscle cells, fibroblasts, corneal endothelium or epithelium, glomerular epithelium, and mesothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocytes, chondrocytes, etc.
- endothelial cells including microvascular endothelial cells
- fibroblasts vascular and other smooth muscle cells
- fibroblasts corneal endothelium or epithelium
- glomerular epithelium glomerular epithelium
- mesothelial cells pericytes
- macrophages monocytes
- monocytes monocytes
- mast cells mast cells
- adipocytes chondrocytes
- vascular smooth muscle cells can be isolated from segments of carotid or femoral arteries obtained from humans (e.g. the patient to be treated or cadaver) or animals. Such isolation procedures are known and may for example involve storing the tissue segments in a suitable sterile medium, such as sterile Medium 199 (Gibco BRL) potentially also containing antibiotic agents such as gentamicin.
- a suitable sterile medium such as sterile Medium 199 (Gibco BRL) potentially also containing antibiotic agents such as gentamicin.
- the artery segment can be slit longitudinally and the endothelial cells removed by rubbing and/or scraping (e.g. with a scalpel blade).
- SMCGM Smooth Muscle Cell Growth Medium
- DMEM Dulbecco's Modified Eagle Medium
- DMEM Dulbecco's Modified Eagle Medium
- the culture medium can be replaced when significant outgrowth of cells from the tissue pieces is observed.
- the cells can then be fed the SMCGM periodically as needed, and conventionally passaged and split. Smooth muscle cell type can be confirmed, for instance by morphological criteria, positive staining for alpha smooth muscle cell actin, and/or other suitable known techniques.
- subconfluent VSMC cultures can be rinsed with calcium-magnesium-free-HBSS (CMF-HBSS) and washed in CMF-HBSS.
- CMF-HBSS calcium-magnesium-free-HBSS
- EDTA trypsin-ethylenediamine tetraacetic acid
- Cells can be pelleted by centrifugation and the pellet re-suspended in SMCGM for cell counting.
- the cell pellet can be re-suspended in SMCGM.
- This cell suspension can then be contacted with the ECM base material to seed the material with the cells.
- the seeded ECM can then be placed into a culture container filled with SMCGM.
- the culture container can be capped and incubated at about 37°C on a roller apparatus.
- the medium in the culture tubes can be periodically replaced and the seeded ECMs can be cultured for a period sufficient to deposit ECM components, for example, from one to twenty days.
- endothelial cells are used to deposit ECM proteins on an ECM base material. For instance, endothelial cells can be caused to attach and spread on the ECM surface, and cultured to deposit the ECM proteins.
- small patches of endothelial cells may be directly harvested from a donor vessel (e.g. a vessel of the patient to be treated, or a cadaver) and seeded onto an ECM surface whereby they will attach and proliferate to cover the ECM surface, and deposit ECM components.
- a donor vessel e.g. a vessel of the patient to be treated, or a cadaver
- enzymatic methods can be used to release endothelial cells (ECs) from arterial or venous vessels obtained from humans or animals.
- the vessel lumina are cannulated, rinsed with HBSS, and filled with an endothelial cell harvesting enzyme solution in a suitable medium such as CMF- HBSS.
- Suitable enzymes include, but are not limited to, collagenase, dispase, and trypsin.
- Endothelial cells are flushed into a sterile centrifuge tube and the ECs pelleted. The cells are then plated onto tissue culture flasks, grown at about 37°C until nearly confluent and then passaged. Endothelial cell type can be confirmed by morphological criteria, by positive staining for Factor VLU, and by uptake of acetylated low density lipoprotein. Subconfluent endothelial cells (passages 2-10, for example) can be rinsed with CMF-HBSS and washed in CMF-HBSS.
- the cells can be harvested by using trypsin-EDTA to release cells from the flasks followed by trypsin neutralization with complete Endothelial Cell Growth Medium (ECGM; 80% Medium 199, 16% fetalbovine serum, 2 mM glutamine, 15 units/ml heparin, 25 ⁇ g/ml gentamicin, 12.5 ⁇ g/ml Endothelial Cell Growth Supplement (Collaborative Biomedical Products, Bedford, Mass.)).
- the cells can be pelleted and the pellet re-suspended in ECGM. This suspension can then be used to seed the ECM base material, and then cultured in association with the ECM base material to secrete and deposit the desired amount of ECM components, for example, one to twenty days.
- the endothelial cell layer can be removed.
- the endothelial cells can be removed by rinsing the graft several times (e.g. three times) with HBSS, and treating with an ammonium hydroxide solution, e.g. about 0.025M ammonium hydroxide, to remove the endothelial cells, and rinsed again several times in HBSS.
- ammonium hydroxide solution e.g. about 0.025M ammonium hydroxide
- Other suitable treatments may include, for example, 0.01-0.5M ammonium hydroxide for about 30 seconds to about 60 minutes.
- Other candidate methods of removing the endothelial cells may include air drying, or treatment with other stripping solutions, for example, chloroform, methanol, ammonium hydroxide, or sodium chloride, either alone or in combination. Other treatments known to those skilled in the art may also be suitable. It is also possible to produce a secreted matrix deposit through a variety of other methods.
- One suitable method for example, involves using mixed culture seeding in which both ECs and SMCs are combined and both cell types are seeded onto the ECM base material simultaneously. After extended co-culture, the secreted matrix will be produced.
- Fibroblasts for use in depositing extracellular matrix proteins may be readily isolated from an appropriate source organ or tissue. This can be readily accomplished using techniques known to those skilled in the art.
- the tissue or organ can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between neighboring cells, making it possible to disperse the tissue into a suspension of individual cells without appreciable cell breakage.
- Enzymatic dissociation can be accomplished by mincing the tissue and treating the minced tissue with any of a number of digestive enzymes either alone or in combination.
- Such enzymes include, but are not limited to, trypsin, chymotrypsin, collagenase, elastase, hyaluronidase, DNase, pronase, and/or dispase etc.
- Mechanical disruption can also be accomplished by a number of methods including, but not limited to the use of grinders, blenders, sieves, homogenizers, pressure cells, insonators, and the like.
- cells which are specialized for the particular tissue implant site, can be cultured on the base ECM material for the production of a tissue type specific extracellular matrix composite.
- the first ECM material can conditioned to create the ECM composite using cells of a given type, and the resulting ECM composite can be configured for and grafted on or in a type of tissue of the patient having cells of that given type.
- dermal fibroblasts can be used to form the three-dimensional subconfluent stroma for the production of skin-specific extracellular composite matrix in vitro.
- stromal cells of hematopoietic tissue including, but not limited to, fibroblast endothelial cells, macrophages/monocytes, adipocytes and reticular cells, can be used to form the three-dimensional subconfluent stroma for the production of a bone marrow-specific extracellular matrix in vitro.
- Hematopoietic stromal cells can be readily obtained from the "buffy coat" formed in bone marrow suspensions by centrifugation at low forces, e. g., 3000x g.
- glial cells can be used as the stroma to support the proliferation of neurological cells and tissues.
- Glial cells for this purpose can be obtained by trypsinization or collagenase digestion of embryonic or adult brain. For certain uses in vivo it may be preferable to obtain the cells from the subject's own tissues.
- the growth of cells in the presence of the ECM base material can be further enhanced by adding to the framework, or coating the framework support with natural or recombinant molecules, including but not limited to, proteins, such as collagens, elastic fibers, reticular fibers, and glycoproteins; glycosaminoglycans, such as heparin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sulfate, etc.; a cellular matrix, and/or other materials, such as whole blood, serum, growth factors, fibronectin, Pronectin F, RGD peptide, or cell or tissue extracts.
- proteins such as collagens, elastic fibers, reticular fibers, and glycoproteins
- glycosaminoglycans such as heparin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate,
- Stem cells may also be used and cultured on the ECM base material to deposit extracellular matrix components.
- adult or embryonic stem cells may be cultured and treated with appropriate differentiation factors to mature and secrete extracellular matrix components.
- the differentiated cell population can then be removed using suitable techniques as described herein.
- the ECM base material is incubated in an appropriate nutrient medium under physiologic conditions favorable for cell growth, i. e., promoting mitosis (cell division).
- Many commercially available media such as RPMI 1640, Fisher's, Iscove's, McCoy's, and the like, may be suitable for use.
- the three-dimensional culture can be suspended or floated in the medium during the incubation period in order to maximize proliferative activity.
- the culture can be "fed” periodically to remove the spent media, depopulate released cells, and to add fresh media.
- the cells are grown to an appropriate degree to allow for adequate deposition of extracellular matrix components.
- the extracellular matrix components are secreted locally by cells and not only bind cells and tissues together but also influence the development and behavior of the cells they contact.
- the typical extracellular matrix contains various fiber-forming proteins interwoven in a hydrated gel composed of a network of glycosaminoglycan chains.
- the glycosaminoglycans are a heterogeneous group of long, negatively charged polysaccharide chains, which (except for hyaluronic acid) are covalently linked to protein to form proteoglycan molecules.
- the fiber-forming proteins are of two functional types: (a) mainly structural (collagens and elastin), and (b) mainly adhesive (such as fibronectin and laminin).
- the fibrillar collagens (types I, II, and LTI) are rope-like, triple-stranded helical molecules that aggregate into long cable-like fibrils in the extracellular space; these in turn can assemble into a variety of highly ordered arrays.
- Type IV collagen molecules assemble into a sheetlike meshwork that forms the core of all basal laminae.
- Elastin molecules form an extensive cross-linked network of fibers and sheets that can stretch and recoil, imparting elasticity to the matrix.
- Fibronectin and laminin are examples of large adhesive glycoproteins in the matrix; fibronectin is widely distributed in connective tissues, whereas laminin is found mainly in basal laminae. By means of their multiple binding domains, such proteins help cells adhere to and become organized by the extracellular matrix.
- a naturally secreted human dermal extracellular matrix contains type I and type LTI collagens, fibronectin, tenascin, glycosaminoglycans, acidic and basic FGF, TGF-beta, KGF, decorin and various other secreted human dermal matrix proteins.
- the various extracellular matrix proteins are produced in the quantities and ratios similar to that existing in vivo.
- the stromal cells in three dimensions will sustain active proliferation of cells in culture for much longer time periods than will monolayer systems. Further, the three-dimensional system supports the maturation, differentiation, and segregation of cells in culture in vitro to form components of adult tissues analogous to counterparts found in vivo. Thus, the extracellular matrix created by the cells in culture is more analogous to native tissues.
- the ECM composite material will be decellularized after deposition of the desired level of non-native ECM components on the ECM base material.
- the tissue may be treated with a solution that releases component cells from the associated extracellular membrane matrix. There are a number of agents and methods that will remove the cells.
- the cell-containing composite material can be treated with a mild chemical stripping solution, such as ammonium hydroxide (NH 4 OH).
- a mild chemical stripping solution such as ammonium hydroxide (NH 4 OH).
- One such treatment may involve incubating the material in an aqueous NH 4 OH solution at a concentration of about 0.01M to about 0.5M, for a period of about 30 seconds to about 60 minutes followed by flushing the vessel lumen or other ECM construct with a buffer solution.
- the treatment may involve treating the cell- containing material with a 0.25M NH 4 OH solution for about 1 to 10 minutes.
- Decellularization may also involve air drying. Following air drying, the material can be flushed with buffer to remove cells and cell components and rehydrate the ECM composite for further processing, if desired.
- the cells can also be removed by exposing the cell-containing material to one or more freeze-thaw cycles, typically followed by removal of dead cells and cell debris.
- removal may be accomplished by flushing the material after freezing with a suitable solution such as HBSS (1.3 mM CaCl 2 , 5 mM KC1, 0.3 mM KH 2 PO 4 , 0.5 mM MgCl 2 , 0.4 mM MgSO 4 , 138 mM NaCl, 4 mM NaHCO 3 , 0.3 mM NaHPO 4 , 5.6 mM glucose).
- Freeze-kill of the cells may be accomplished, for instance, by flash-freezing the living cells in liquid nitrogen.
- the cells may also be killed by irrigating the inoculated three-dimensional framework with sterile water, such that the cells burst in response to osmotic pressure.
- a mild detergent rinse such as EDTA, CHAPS or a zwitterionic detergent
- a cryoprotectant such as DMSO, propylene glycol, butanediol, raffinose, polyvinyl pyrrolidone, dextran or sucrose and vitrified in liquid nitrogen.
- the cell-containing material can be subjected to enzymatic digestion and/or extracting with reagents that break down the cellular membranes and allow removal of cell contents.
- detergents include non-ionic detergents (for example, TRITON X-100, octylphenoxy polyethoxyethanol, (Rohm and Haas); BRJJ-35, a polyethoxyethanol lauryl ether (Atlas Chemical Co.), TWEEN 20, a polyethoxyethanol sorbitan monolaureate (Rohm and Haas), LUBROL-PX, or polyethylene lauryl ether (Rohm and Haas)); and ionic detergents (for example, sodium dodecyl sulphate, sulfated higher aliphatic alcohol, sulfonated alkane and sulfonated alkylarene containing 7 to 22 carbon atoms in a branched or unbranched chain).
- ionic detergents
- Enzymes can be used also and can include nucleases (for example, deoxyribonuclease and ribonuclease), phospholipases and lipases.
- nucleases for example, deoxyribonuclease and ribonuclease
- phospholipases for example, phospholipases and lipases.
- lipases can be treated with a fixative, if desired. This fixation can be accomplished by placing the graft into a fixing solution, such as, for example, glutaraldehyde in a suitable buffer.
- Suitable buffers may include, but are not limited to, N-2-hydroxyethylpiperazine- N'-2-ethane sulfonic acid (HEPES), acetate, 2-(N-morpholino) ethanesulfonic acid (MES), 3-[N-morpholino] propanesulfonic acid (MOPS), tris hydroxymethyl aminomethane, phosphate, and others. Any remaining aldehyde reactive sites can be blocked with an amino group containing solution.
- Suitable reagents for this procedure include, but are not limited to, 0.1M glycine, Medium 199, Dulbecco's Modified Eagle Medium, and other physiological culture media, for example.
- ECM composite graft materials of the invention can be manufactured in a variety of physical forms, to suit a variety of medical applications.
- the graft materials may be formed as sheets, tubes, or other three-dimensional shapes.
- the configuration of the ECM composite material may be attained before or after deposition of the non-native ECM components on the ECM base material.
- an ECM composite material can be manufactured in larger, bulk dimensions, and then divided into smaller products.
- the ECM base material may provided in a naturally-derived layer form, or may itself be a manufactured article, such as a sponge or cast sheet, prepared from a naturally- derived ECM material.
- ECM composite grafts of the invention may be used in a wide variety of medical (including veterinary) applications.
- Examples of specific tissues which can be repaired and/or reconstructed using the inventive ECM composite materials included nervous tissue, skin, cardiovascular tissue (including vascular tissue and cardiac tissue), pericardial tissue, muscle tissue, ocular tissue, periodontal tissue, bone, connective tissue such as tendons or ligaments, and others.
- the ECM composites of the present invention can be formed into grafts taking the forms of powders, fluidized compositions, sheets, tubes, pouches, multi-ply constructs, single-ply constructs, and constructs in combination with other medical devices or implements such as stents, valves, catheters, sutures, staples, balloons, metal coils, synthetic meshes, biodegradable polymers, inert polymers, non-biodegradable polymers, other collagenous matrices, stem cells, vectors for gene delivery, other naturally-occurring, synthetic, or recombinant bioactive molecules, or in combination with other combinations of these medical devices or implements.
- other medical devices or implements such as stents, valves, catheters, sutures, staples, balloons, metal coils, synthetic meshes, biodegradable polymers, inert polymers, non-biodegradable polymers, other collagenous matrices, stem cells, vectors for gene delivery, other naturally-occurring, synthetic, or
- the ECM composites of the present invention can be formed into a powder tissue graft composition.
- the ECM composite material can be comminuted by tearing, cutting, grinding, shearing or the like, frozen or not, in a manner similar to that described for other collagen-based ECMs in U.S. Patent No. 5,275,826, International Publications Nos. WO 96/32146, WO 98/22158 and WO 98/25636; the disclosures of which are expressly incorporated herein by reference.
- ECM composite powders of the invention can be used to repair bone tissue, for instance using the general techniques described in U.S. Patent No. 5,641,518.
- a powder form of the ECM composite can be implanted into a damaged or diseased bone region for repair.
- the ECM composite powder can be used alone, or in combination with one or more additional bioactive agents such as physiologically compatible minerals, growth factors, antibiotics, chemotherapeutic agents, antigen, antibodies, enzymes, vectors for gene delivery and hormones.
- the powder-form implant will be compressed into a predetermined, three-dimensional shape, which will be implanted into the bone region and will substantially retain its shape during replacement of the graft with endogenous tissues.
- the ECM composites of the invention may be fluidized following techniques as described in U.S. Patent No. 5,275,826, the disclosure of which is incorporated herein by reference.
- Fluidized form of the composite ECMs are generally prepared by solubilization by enzymatic digestion, including the use of protease, such as trypsin or pepsin, or other appropriate enzymes such as a collagenase or a glycosaminoglycanase, or the use of a mixture of enzymes, for a period of time sufficient to solubilize the tissue and form a substantially homogeneous solution. While a fluidized composition may be formed from enzyme digestion of comminuted tissues, a procedure involving only enzyme digestion with no mechanical commination can also be used.
- the ECM composites can be provided as sheet constructs.
- the ECM composites can be spread out into a native sheet form, trimmed to size if desired, and lyophilized.
- Multi-layer sheet constructs can be made including two or more such sheets stacked directly atop one another. In this regard, these constructs can be stabilized by bonding the collagen sheets together, for example by compressing the sheets under dehydrating conditions, use of crosslinkers, or other suitable means. Larger area sheet constructs can be prepared by overlapping and fusing together of several smaller area ECM sheets. The construction of a large area sheet from smaller area sheets has been described in U.S. Patent No. 5,127,903, International Publication No. WO 96/32146, and ASAIO Journal, 2000, 46:268- 272.
- the small area sheets are fused together by compressing the overlapped edges of these sheets under dehydrating conditions.
- the sheets are joined by photocrosslinking in the presence of a photo- catalytic dye.
- Other standard tissue bonding techniques known to those skilled in the art, including the use of sutures, crosslinking agents, adhesives and pastes can also be used.
- the smaller area sheets can be bonded or fused together to form a larger area sheet before or after the deposition of the non-native ECM components and decellularization steps described above.
- the composite ECM matrices can be configured into tubes of various dimension and thickness to provide tubular tissue grafts useful in, for example, vascular, urinary tract or nervous system repair or replacement.
- tubular grafts may be used in coronary artery and peripheral artery replacement, or the like, e.g. with the graft having an internal diameter of about three to six millimeters.
- Techniques for making tubular grafts from collagenous sheets have been generally described in U.S. Patent Nos. 2,127,903 and 4,902,508 and International Publication No. WO 98/22158, the disclosures of which are expressly incorporated herein by reference.
- a tubular graft may be constructed by manipulating sheets of the ECMs to define a tube and suturing, bonding or otherwise securing the longitudinal seam to form an appropriately- dimensioned tubular graft having a lumen.
- the tube may be formed so as to present a lumenal and/or outer surface comprising the deposited ECM material.
- the tubular construct is formed over a sterile rod or mandrel having an outer diameter approximating that of the recipient vessel to be grafted.
- at least one sheet layer of the inventive ECM composite is wrapped about the rod to form an overlapping seam.
- the overlapped seam may be joined together by any of the conventional methods such as suturing, photocrosslinking, radiation crosslinking, fusion under compression and dehydration, or by adhesive and the like.
- the tubular grafts may be constructed from multiple layers of ECMs, with the number of layers used generally depending on the strength requirement of the particular application.
- vascular grafts can be constructed with multiple layers of ECM sheets to ensure that they can withstanding the constant pulsating pressure of their implanting environment.
- composite ECMs of the invention can be used as exterior, interior or other coverings for supporting structures such as stents, grafts, etc. These applications include, for example, use with self-expanding or otherwise expandable stents, both to form biocompatible coverings such as sleeves and to form leaflets or other valve structures (see, e.g. WO9962431 published December 9, 1999 and WO 119285 published March 22, 2001, both hereby incorporated herein by reference).
- the ECM composite material can be attached to a stent in a fashion whereby it forms one, two, or more leaflets, cusps, pockets or similar structures that resist flow in one direction relative to another.
- such devices constructed as vascular valves are implanted to treat venous insufficiencies in humans, for example occurring in the legs.
- valves for treating these or other valve deficiencies may be surgically created without the use of a stent or other supporting structure.
- Tubular grafts containing the ECM composite material of the invention may also be prepared as disclosed in International Publication No. WO 2004/022107 published March 18, 2004, which claims the benefit of U.S. Patent Application Serial No.
- All or some of the layers of the disclosed tubular grafts may contain an ECM composite material of the present invention, and in particular embodiments at least the lumenal surface of the tubular constructs will contain the second ECM material.
- a pre-manufactured ECM composite material may be fashioned into such disclosed constructs, or the overall construct may be prepared including the first ECM material, and then the second ECM material deposited onto the first ECM material followed by decellularization as disclosed herein.
- FIG. 1 shown in Figure 1 is a perspective view of a tubular graft prosthesis 10.
- Tubular graft prosthesis 10 defines an inner lumen 11 and has a length L and diameter D rendering the construct suitable for the intended use, for example a vascular use.
- FIG 2 shown in Figure 2 is a cross-sectional view of the prosthesis 10 of Figure 1 taken along line 2-2 and viewed in the direction of the arrows.
- Prosthesis 10 has walls defining inner lumen 11, preferably including several layers of material as illustrated.
- shown in prosthesis 10 is a first tubular layer 12, a second layer tubular layer 13, a third tubular layer 14, a fourth tubular layer 15, and a fifth tubular layer 16.
- At least one of these layers may include juvenile submucosa from a warm-blooded vertebrate animal, or otherwise include an intact tubular submucosa segment having a small native internal diameter (12 mm or less).
- the animal is preferably a mammal, such as a porcine, ovine, bovine, or other mammalian animal. Human donor tissues may also be used in the present invention.
- porcine submucosa the animal at harvest will typically not exceed about 10 kilograms (kg).
- the juvenile or other small diameter submucosa tissue will retain its intact, tubular form as harvested from the animal. More preferably, at least the innermost layer 12 will be formed from intact, tubular juvenile submucosa tissue.
- Preferred devices will include at least one additional layer, for example, layers 13, 14, 15 and 16 as illustrated in Figure 2. These additional layers can be made of any suitable material and desirably provide reinforcement and strength to the device supplemental to that provided by innermost layer 12.
- layers 13, 14, and 15 may, for example, be formed of synthetic materials such as synthetic polymer materials. Suitable synthetic materials may be biodegradable or non-biodegradable materials.
- biocompatible polymers such as cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or mixtures or copolymers thereof; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxy-butyrate valerate, polyhydroxyalkanoate, or another biodegradable polymer.
- synthetic biocompatible polymers such as cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or mixtures or copolymers thereof; polylactic acid, poly
- one or more of, and potentially all of layers 13, 14, 15 and/or 16 are formed from additional collagenous materials.
- suitable collagenous materials include extracellular matrix layers including, for instance, submucosa, renal capsule membrane, dura mater, pericardium, serosa, peritoneum or basement membrane layers, including liver basement membrane. These layers may be isolated and used as intact membranes, or reconstituted collagen layers including collagen derived from these materials or other collagenous materials may be used.
- layers 13, 14, 15 and 16 are made from additional submucosa tissue layers.
- Suitable submucosa tissues for these purposes include, for instance, intestinal submucosa including small intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa.
- Small intestinal submucosa when employed, can be used in an intact, native tubular form or can be a tubular form shaped from flat sheets including one or more seams along all or a portion of its length.
- at least one of layers 13, 14, 15 and 16 will include adult submucosa tissue, as such tissue in its native condition is generally superior in mechanical properties to juvenile submucosa tissue. In this fashion, adult submucosa tissue can be used to provide strength to the overall graft construct 10.
- Porcine small intestinal submucosa is particularly preferred for these purposes.
- intermediate layers 14 and 15 can be made from adult small intestinal submucosa
- intermediate layer 12 and outermost layer 16 can be made from juvenile small intestinal submucosa, preferably again in its native, intact tubular form.
- seamless inner layer 12 and seamless outer layer 16 can be provided.
- Layers 12, 13, 14, 15 and 16 can be adhered to one another so as to generally form a unitary construct. This adherence may be achieved, for example, by crosslinking, including for example dehydrothermal crosslinking or chemical crosslinking, and/or by the use of a bonding agent.
- tubular devices of the invention may be prepared, for example, by positioning the appropriate tissue layers over a mandrel, and subsequently bonding or adhering the tissue layers together to form a generally unitary tubular construct. This may be accomplished, for instance, using intact tubes, and/or by wrapping or winding sheet- or strip-form adult submucosa tissue around the mandrel to form overlapped sections which are subsequently bonded or adhered.
- an outermost covering layer may be provided by an intact juvenile submucosa segment positioned over the underlying tissue layers.
- tubular prosthesis devices are prepared using a two component bonding agent such as fibrin glue (e.g., having thrombin and fibrinogen as separate components). To prepare such devices, subsequent layers are added after coating the previously-applied layer with a first component of the bonding agent (e.g., thrombin) and coating a layer to be applied with a second component of the bonding agent (e.g., fibrinogen).
- a two component bonding agent such as fibrin glue (e.g., having thrombin and fibrinogen as separate components).
- a first component of the bonding agent e.g., thrombin
- a second component of the bonding agent e.g., fibrinogen
- FIG. 3A An intact tubular submucosa segment 21 from a juvenile animal may first be positioned over a mandrel 20 as depicted in Fig. 3A, to provide a one-layer (IL) construct. Thrombin (light shading, Fig. 3B) is then applied to the intact segment 21.
- IL one-layer
- a second intact tube of juvenile submucosa 22 is provided either on an extension of the same mandrel as illustrated, or on a second mandrel connectable to the first mandrel.
- the second intact segment 22 is coated with fibrinogen (dark shading), and the segment 22 is positioned immediately adjacent the first segment 21. Segment 22 is then and pulled over the first submucosa tube in a fashion causing inversion of the tube 22 (Figs. 3C-3E).
- leading end 25 of segment 22 remains substantially in place, but inverted, in contact with the trailing end 23 of segment 21.
- Trailing end 26 of segment 22 finally inverts and comes into contact with leading end 24 of the first segment 21.
- the adult submucosa is then wrapped around the 2L construct for a single turn (clockwise rotation in Figs. 3F-3G), resulting in a completed three-layer (3L) construct on the mandrel 20.
- thrombin is applied to the outer surface of the 3L construct (light shading, Fig. 31).
- a second turn of the adult submucosa sheet 27 is then completed (Fig.
- a third intact tubular juvenile submucosa segment 28 (Fig. 3K) is positioned adjacent to the applied layers, thrombin (light shading) is coated onto the 4L construct and fibrinogen (dark shading) is coated onto the third tubular segment 28.
- the third tubular segment 28 is then pulled and inverted over onto the applied layers (Figs. 3K-3M) as before to complete the 5L construct (Fig.
- the device is then allowed to cure and is trimmed as necessary.
- the application of thrombin and fibrinogen or any other two- components for the bonding agent could be reversed in order.
- the components of the bonding agents can be applied by any suitable method, including spray or brush application methods, and intermediate constructs can be hydrated at appropriate points in the manufacture.
- the entire construct may then be freeze-dried or otherwise processed (e.g. to deposit the second ECM material on lumenal or other surfaces) if desired.
- ECM composite matrices of the invention can optionally be preconditioned for orthopedic or other applications, again before or after deposition of ECM components and removal of the depositing cells.
- Preparation of orthopedic grafts have been generally described in U.S. Patent Nos. 2,127,903; 5,281,422; 5,275,826; and 5,352,463, the disclosures of which are expressly incorporated herein by reference.
- Conditioning alters the viscoelastic property and reduces the strain inherent in the native ECMs sheets.
- the ECMs may be conditioned by stretching, chemical treatment, enzymatic treatment or exposing the tissue to other environmental factors, or any other art known methods.
- the ECMs can be conditioned by stretching under a load to a predetermined percentage of the pre- stretched length.
- the ECMs may be conditioned by suspending a weight from a segment of an ECM sheet for a period of time sufficient to allow about 10% to about 20% elongation of the segment.
- the ECM segment can then be configured, alone or in combination with other segments, to a variety of shapes to serve as orthopedic grafts.
- ECM composites of the invention can be used for the repair and/or replacement of connective tissues.
- connective tissues include bone, cartilage, tendons and ligaments.
- the composite ECMs may serve as ligament or tendon replacement or a patch for a broken or severed tendon or ligament.
- the end portions of the graft construct may be formed, manipulate or shape the end portions of the graft construct to be attached, for example, to a bone structure, in a manner that will reduce the possibility of graft tearing at the point of attachment.
- the conditioned ECM composite graft material can be folded or partially everted to provide multiple layers for gripping, for example, with spiked washers or staples.
- a ECM material can be folded back on itself to join the end portions to provide a first connective portion to be attached, for example, to a first bone and a bend in the intermediate portion to provide a second connective portion to be attached to a second bone articulated with respect to the first bone.
- one of the end portions of the ECM graft can be adapted to be pulled through a tunnel in, for example, the femur and attached thereto, while the other of the end portions may be adapted to be pulled through a tunnel in the tibia and attached thereto to provide a substitute for the natural cruciate ligament, the segment being adapted to be placed under tension between the tunnels to provide a ligament function, i.e., a tensioning and position function provided by a normal ligament.
- ECM composite sheets of the present invention can also be used to provide an orthopedic graft for use as connective tissue to hold fractured bone pieces together and in proper orientation in the body, the tissue segment being formed to serve as a fracture wrap about segments of fractured bone and to be attached to the bone.
- the first ECM (base) material can be disinfected and/or sterilized by contact with a suitable agent such as peracetic acid or another oxidizing disinfectant prior to seeding with the cells to be used to deposit the second ECM material, during removal of such cells, after removal of such cells, or any combination of these.
- a suitable agent such as peracetic acid or another oxidizing disinfectant
- Such disinfection/sterilization techniques may for example be conducted using agents and general conditions as disclosed in
- the ECM composite graft constructs and compositions of the invention can be packaged to protect the purity of the constructs/compositions for storage and shipment to the consumers.
- dried graft constructs are packaged in pre-sterilized bags and then vacuum sealed. These packages may be stored and shipped at room temperature.
- graft constructs that are in a hydrated state are packaged in pre-sterilized bags and then vacuum sealed. The hydrated samples may be stored and shipped frozen.
- the pre-sterilized bags are formed of materials that are impervious to moisture and oxygen, e.g., PETE.
- the sealed packages may be irradiated to decimate pathogens that were inadvertently collected on the surface of the constructs during manufacturing.
- dried graft constructs can be packaged in non-sterile gas permeable bags and then vacuum-sealed. The packaged constructs are then sterilized along with the gas permeable packaging using ethylene oxide gas. It is contemplated that still other conventional techniques for sterilization which are within the knowledge of those of ordinary skill in the arts may also be used, including for example radiation and plasma sterilization techniques.
- Tissue graft compositions including ECM composites of the invention can be administered to a vertebrate host in an amount effective to induce endogenous tissue growth at a site in the host in need of same due to the presence of damaged or diseased tissue.
- the vertebrate host may be autogenic, allogenic or xenogenic to the animals from which the base ECMs were harvested, and/or to the cells used to deposit the ECM components on the ECM base material.
- the vertebrate host is a human
- the ECM base material is allogenic or xenogenic
- the ECM-depositing cells are autogenic, allogenic or xenogenic to the human host.
- the base ECM is xenogenic and the ECM-depositing cells are autogenic to the human recipient of the ECM composite graft
- the base ECM is xenogenic and the ECM-depositing cells are human and allogenic to the recipient of the ECM composite graft.
- the isolated extracellular matrix composite material can be used to prepare a cell-seeded graft, if desired.
- cells allogenic or autogenic to the recipient of a graft of the composite material can be seeded and optionally proliferated on the composite material, which can then be implanted, along with the cells, into the recipient.
- Any of the cell types disclosed above for deposit of the second extracellular matrix material can also be used in such cell-seeded grafts, including combinations of such cell types.
- the first extracellular matrix material will be xenogenic to a human recipient (e.g.
- Fluidized composite ECMs of this invention may be used in orthopedic applications, e.g. tissue replacement, augmentation, and/or repair. It is contemplated that fluidized ECMs of the present invention may be used as an injectable heterograft. By injecting an effective amount of a fluidized ECMs composition into the location of a tissue defect, for example, in bone or soft tissues in need of repair or augmentation, one can readily take advantage of the biotropic properties of the ECMs.
- the fluidized composition can be used advantageously as a filler for implant constructs, e.g., in cosmetic or trauma-treating surgical procedures.
- Composite ECMs of the invention can also be used in body wall repair, including for example in the repair of abdominal wall defects such as hernias, using techniques analogous to those described in Ann. Plast. Surg., 1995, 35:374- 380; and J. Surg. Res., 1996, 60:107-114.
- preferred ECM tissue grafts of the invention promote favorable organization, vascularity and consistency in the remodeled tissue.
- composite ECMs of the invention can be used in the repair of partial or full thickness wounds and in dermal augmentation using general grafting techniques which are known to the art and literature (see, e.g. Annals of Plastic Surgery 1995, 35:381-388).
- general grafting techniques which are known to the art and literature (see, e.g. Annals of Plastic Surgery 1995, 35:381-388).
- cultured epidermal grafts preferably cultured epidermal autografts, or CEA's
- Such cultured grafts have typically involved transplanting keratinocytes and/or fibroblasts onto the dermal substitute.
- the composite ECMs can be used as the dermal substitute, for example in sheet form, and the CEA provided on the composite ECMs.
- keratinocytes can be transplanted, for example by seeding or transferring a keratinocyte sheet, onto the denser side of the composite ECM sheet and fibroblasts can be transplanted also on the more areolar side of the composite ECM sheet.
- Composite ECMs of the invention can also be used in tissue grafts for urogenital applications. For instance, a large area composite ECM sheet can be used for the repair of urinary bladder, in which the composite ECM sheet provides a scaffold for bladder tissue regeneration.
- Tubular grafts including composite ECMs may be used for the repair and replacement of the urinary tract.
- a tubular graft of a specific diameter and strength, the making of which has been previously described, can be surgically substituted for a damaged or diseased urinary tract by standard surgical techniques.
- Technique for urinary tract replacement has been described generally in "Use of Reconstructed Small Intestine Submucosa for Urinary Tract Replacement", by Xie et. al, in ASAIO Journal 2000, p.
- inventive composite ECMs can also find use in an endoscopic injection procedure to correct vesicureteral reflux.
- a submucosal injection can be made, for instance in the area under the ureteral orifice of a patient, to induce smooth muscle growth and collagen formation at the injection site.
- tissue graft constructs formed with composite ECMs of the present invention can be used in neurological applications. For example, in techniques requiring a dural substitute to repair defects due to trauma, tumor resection, or decompressive procedures.
- ECM composites of the invention can be utilized as cell growth substrates for in vitro cultivation of eukaryotic or other cells. These applications employ techniques in the art which have been applied to other naturally-derived ECMs or synthetic graft materials and can be similarly undertaken using the composite ECMs of the present invention. Typically, the composite ECM composition will be combined with various nutrients, growth factors, minerals and salts known in the art to be important for the particular cell types.
- the inventive composite ECMs can also serve as a collagenous matrix in compositions for producing transformed cells. The techniques for cell transformation have been described in International Publication Nos. WO 96/25179 and WO 95/22611; the disclosures of which are expressly incorporated herein by reference.
- purified composite ECMs of the present invention for example in fluidized or paste form, is included in the cell transformation compositions, in combination with a recombinant vector (e.g. a plasmid) containing a nucleic acid sequence with which in vitro or in vivo target cells are to be genetically transformed.
- a recombinant vector e.g. a plasmid
- a nucleic acid sequence with which in vitro or in vivo target cells are to be genetically transformed for the purpose of promoting a further understanding of the present invention.
- EXPERIMENTAL 1 Summary Human umbilical vein endothelial cells (HUVEC) were grown for two weeks on [ptvomr SIS and then removed to leave behind intact human basement membranematerials. The resultilng composite ECM material was termed "conditioned" SIS (c-SIS). When re-seeded on c-SIS, HUVEC exhibited enhanced organization of cell junctions and had increased metabolic activity compared to cells on native SIS (n-SIS). HUVEC grown on c-SIS also released lower amounts of the pro-inflammatory prostaglandin PGI 2 into the media compared to cells grown on n-SIS. Additionally, adhesion of resting or activated human platelets to c-SIS was significantly decreased as compared to n-SIS. Conditioning of porcine SIS by human endothelial cells was thus demonstrated to improve key biological properties of the material. Statistical analysis for this Experimental was made by ANOVA and p ⁇ 0.05 was considered significant.
- EGM Human umbilical vein endothelial cells
- Clonetics East Rutherford, NJ
- EGM Endothelial growth media
- EGM contains 2% fetal bovine serum, 12 .tg/ml bovine brain extract, I ⁇ g/ml human epidermal growth factor, and I ⁇ g/ml hydrocortisone, getamicin, and amphotericin B.
- HUVEC were maintained at 5% CO 2 at 37°C, and passages 1-4 were used for experiments.
- SIS was obtained from Cook Biotech, Inc.
- Temecula, CA 10 ⁇ g/ml human fibronectin (Sigma Chemcial Co., St. Louis, MO); 1/5 .tg/ml human laminin (Sigma Chemical Co., St. Louis, MO); 0.5 tg/ml human vitronectin (Chemicon International, Temecula, CA).
- HUVECs at passage 2 were seeded onto the glass slides at 75,000 cells/mm 2 and cultured for 72 hours prior to fixation with 4% paraformaldehyde.
- SDS soduim dodecyl sulfate
- SIS surface of SIS was scraped directly in SDS sample buffer and an antibody specific for the cellular enzyme anti- mitochondrial-8-oxoguanine DNA-glycosylase (ab6491), Abeam Limited (Cambridge, UK) or for ( ⁇ -catenin along with the appropriate horseradish peroxidase-labeled secondary antibodies (Jackson) was used to detect the presence of cells on SIS.
- an antibody specific for the cellular enzyme anti- mitochondrial-8-oxoguanine DNA-glycosylase (ab6491), Abeam Limited (Cambridge, UK) or for ( ⁇ -catenin along with the appropriate horseradish peroxidase-labeled secondary antibodies (Jackson) was used to detect the presence of cells on SIS.
- Cell adhesion to SIS was measured using metabolically labeled HUVEC.
- Cells were grown in 150 mm 2 tissue culture dishes and labeled for 16 hours in 25 ⁇ Ci of 35 S-methionine, rinsed in PBS and then removed from the dish using trypsin.
- 35 S-methionine labeled HUVEC were resuspended in growth media and equal numbers of cells (100,000/cm 2 ) were added to n-SIS or c-SIS and allowed to adhere for varying lengths of time as indicated. After the adhesion period, SIS was washed with PBS to remove unbound cells and the amount of radioactivity remaining on the SIS was measured using a liquid scintillation counter.
- Metabolic activity assessment To estimate the relative metabolic rates of cells grown on n-SIS and c-SIS, cells were seeded at 100,000 or 200,000 cells/cm 2 and cultured for one hour to two weeks. Metabolic activity was assessed using CellTiter 96 Aqueos Once Solution Cell Proliferation Assay obtained from Promega (Madison, Wl). The assay is a colorimetric method, which measures the amount of NADPH produced by dehydrogenase enzymes in metabolically active cells by determining the amount of colored reaction product (Formazan) that can be produced from MTS tetrazolium compound (Owen's reagent) in media samples.
- Formmazan colored reaction product
- EGM media for 1 hour. The media was collected and centrifuged at 14,000 x g for 2 min to pellet any particulates, and the supernatant was retained for prostacyclin measurement. 6-keto Prostaglandin Fi a EIA kit was obtained from Cayman Chemical (Ann Arbor, MI) and used to determine the amount of PGI 2 present in each sample.
- Platelet adhesion assays Preparation of Platelets: Whole blood was drawn by venipuncture from healthy aspirin-free human donors and collected in ACD (83 mM soduim citrate, 111 mM glucose, 71.4 mM citric acid, ph 4.5 ; 1:7, v/v). Platelet-rich plasma was isolated by centrifugation at 250 g for 20 min, and prostaglandin El (0.1 mM) or prostaglandin 12 (50 ng/ml) was added.
- ACD 83 mM soduim citrate, 111 mM glucose, 71.4 mM citric acid, ph 4.5 ; 1:7, v/v.
- Platelet-rich plasma was isolated by centrifugation at 250 g for 20 min, and prostaglandin El (0.1 mM) or prostaglandin 12 (50 ng/ml) was added.
- the platelet-rich plasma was centrifuged for 15 min at 850 x g, and the platelets were resuspended in Hepes-buffered saline ((Buffer A) 10 MM Hepes, pH 7.4, 138 mM NaCl, 12 mM NaHCO3, 10 mM KCI, 5.5 mM glucose, 0.35%BSA, 2 units/ml heparin and I unit/ml apyrase). Resuspended platelets were washed three times in Buffer A without BSA or inhibitors and the concentration was adjusted to (0.5-1.0) x 10 9 platelets/ml. The platelets were then labeled with 51 Cr (0.5 mCi) for 60 min.
- Buffer A 10 MM Hepes, pH 7.4, 138 mM NaCl, 12 mM NaHCO3, 10 mM KCI, 5.5 mM glucose, 0.35%BSA, 2 units/ml heparin and I unit/ml a
- HUVEC grown on glass slides were confluent by 2 days after seeding and exhibited a typical cobblestone appearance characteristic of endothelial cells in culture and similar to the morphology of endothelial cells in vivo (Fun- YC, Biomechanics: Motion, Flow, Stress, and Growth. 1990, New York: Springer- Verlag New York Inc. 196-225.)
- HUVEC grown on SIS at the same initial seeding density of 100,000 cells/mm 2 for 2 days did not form a confluent monolayer with well- developed cell-cell junctions. We found that 5 days after seeding, HUVEC formed a confluent monolayer when grown on SIS. 1.2.2.
- HUVEC conditioned SIS HUVEC were seeded on SIS and grown for 14 days to allow sufficient time for the cells to deposit human matrix proteins onto the surface of the porcine SIS. Thus, HUVEC were cultured for approximately 9 days after reaching confluency. HUVEC were then removed from the SIS using NH4OH as has been described previously (Gonzales M, Weksler B, Tsuruta D, Goldman RD, Yoon KJ, Hopkinson SB, Flitney FW, and Jones JC. Structure and function of a vimentin- associated matrix adhesion in endothelial cells.
- FIG. 5A shows microscopy images of untreated SIS, SIS with cells grown for 14 days and left intact, and SIS with cells removed (conditioned) that were stained with Hoechst dye to label cell nuclei to verify that all cells were removed from the SIS. Confirmation that all cells were removed was also made by immunoblotting for the cellular proteins (3- catenin and mitochondrial-DNA8-oxanine-glycosylase ( Figure 5B).
- HUVEC attachment is not different on c-SIS compared to n-SIS Materials were next evaluated to determine whether there was a difference in initial cell adhesion during the first 1-48 hours after seeding HUVEC onto n-SIS and c-SIS ( Figure 8).
- HUVEC growing on tissue culture plastic were labeled with 3 S-methionine for 18 hours during log phase growth to allow incorporation of the radioactive label into newly synthesized proteins. The cells were washed free of unincorporated radioactivity in the media and the labeled cells were collected by brief trypsinization. Equal numbers of cells were seeded onto n-SIS or c-SIS and allowed to adhere.
- HUVEC grown on c-SIS exhibited a significant increase in NADPH production after 24 hours in culture.
- NADPH production by HUVEC remained significantly higher in cells grown on c-SIS compared to n-SIS through the first 96 hours.
- NADPH levels were not different between groups; after 240 hours in culture NADPH production had dropped significantly below initial levels for both substrates and were not significantly different from each other.
- n-SIS was also coated with commercially available human fibronectin to determine if coating with this single ECM protein known to be present in c-SIS could mimic the decrease in platelet adhesion seen on c-SIS.
- human fibronectin consistently reduced platelet adhesion by approximately 6-15% in each of three independent experiments compared to uncoated nSIS, this difference failed to consistently achieve statistical significance (not shown).
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0605898A GB2423934B (en) | 2003-09-04 | 2004-09-07 | Extracellular matrix composite materials, and manufacture and use thereof |
AU2004270239A AU2004270239C1 (en) | 2003-09-04 | 2004-09-07 | Extracellular matrix composite materials, and manufacture and use thereof |
CA2536923A CA2536923C (en) | 2003-09-04 | 2004-09-07 | Extracellular matrix composite materials, and manufacture and use thereof |
US11/368,077 US7795027B2 (en) | 2003-09-04 | 2006-03-03 | Extracellular matrix composite materials, and manufacture and use thereof |
US12/399,635 US9186435B2 (en) | 2003-09-04 | 2009-03-06 | Extracellular matrix composite materials, and manufacture and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50002603P | 2003-09-04 | 2003-09-04 | |
US60/500,026 | 2003-09-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/368,077 Continuation US7795027B2 (en) | 2003-09-04 | 2006-03-03 | Extracellular matrix composite materials, and manufacture and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005023321A2 true WO2005023321A2 (en) | 2005-03-17 |
WO2005023321A3 WO2005023321A3 (en) | 2005-12-22 |
Family
ID=34272902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/029016 WO2005023321A2 (en) | 2003-09-04 | 2004-09-07 | Extracellular matrix composite materials, and manufacture and use thereof |
Country Status (5)
Country | Link |
---|---|
US (2) | US7795027B2 (en) |
AU (1) | AU2004270239C1 (en) |
CA (1) | CA2536923C (en) |
GB (1) | GB2423934B (en) |
WO (1) | WO2005023321A2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008154149A2 (en) * | 2007-06-07 | 2008-12-18 | Zimmer Orthobiologics, Inc. | Tissue processing for nonimmunogenic implants |
WO2009005596A1 (en) * | 2007-07-03 | 2009-01-08 | Histogenic Corp. | Double-structured tissue implant and a method for preparation and use thereof |
WO2009089110A2 (en) * | 2008-01-04 | 2009-07-16 | Boston Scientific Scimed, Inc. | Methods for repair and regeneration of bone marrow |
EP2113263A3 (en) * | 2008-04-30 | 2010-03-17 | Aesculap AG | Implant, in particular for restoring and/or regenerating human and/or animal tissue |
US20100082114A1 (en) * | 2008-04-29 | 2010-04-01 | Peter Gingras | Tissue repair implant |
US7795027B2 (en) | 2003-09-04 | 2010-09-14 | Cook Biotech Incorporated | Extracellular matrix composite materials, and manufacture and use thereof |
WO2011028521A3 (en) * | 2009-09-02 | 2011-07-14 | Lifecell Corporation | Vascular grafts derived from acellular tissue matrices |
US8070827B2 (en) | 2007-07-03 | 2011-12-06 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
US8187619B2 (en) | 2006-10-23 | 2012-05-29 | Cook Biotech Incorporated | Enhanced compositions containing cells and extracellular matrix materials |
WO2011150055A3 (en) * | 2010-05-25 | 2012-07-12 | Cook Biotech Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
US8435305B2 (en) | 2010-08-31 | 2013-05-07 | Zimmer, Inc. | Osteochondral graft delivery device and uses thereof |
CN103263694A (en) * | 2013-05-14 | 2013-08-28 | 北京华信佳音医疗科技发展有限责任公司 | Collagen-based dura and preparation method thereof |
US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
US8801725B2 (en) | 2008-03-10 | 2014-08-12 | Zimmer Orthobiologics, Inc. | Instruments and methods used when repairing a defect on a tissue surface |
US9113916B2 (en) | 2010-08-31 | 2015-08-25 | Zimmer, Inc. | Drill bit for osteochondral drilling with guiding element and uses thereof |
US9149562B2 (en) | 2007-07-03 | 2015-10-06 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
EP1863545B1 (en) * | 2005-03-19 | 2015-11-18 | Cook Biotech, Inc. | Prosthetic implants including ECM composite material |
US9421304B2 (en) | 2007-07-03 | 2016-08-23 | Histogenics Corporation | Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
CN115337458A (en) * | 2022-08-16 | 2022-11-15 | 尧舜泽生物医药(南京)有限公司 | Cell matrix nerve graft for repairing peripheral nerve injury and preparation method thereof |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050113855A1 (en) * | 2003-08-11 | 2005-05-26 | Kennedy Kenneth C.Ii | Surgical implant |
EP1686903B1 (en) | 2003-11-28 | 2014-07-30 | Cook Medical Technologies LLC | Vascular occlusion devices |
CA2560876A1 (en) | 2004-03-29 | 2005-10-13 | Cook Biotech Incorporated | Medical graft products with differing regions and methods and systems for producing the same |
US9072816B2 (en) * | 2006-01-18 | 2015-07-07 | Cormatrix Cardiovascular, Inc. | Composition for modulating inflammation of cardiovascular tissue |
US8568761B2 (en) * | 2005-07-15 | 2013-10-29 | Cormatrix Cardiovascular, Inc. | Compositions for regenerating defective or absent myocardium |
US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
US8974542B2 (en) | 2006-06-27 | 2015-03-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biodegradable elastomeric patch for treating cardiac or cardiovascular conditions |
US8790414B2 (en) * | 2006-11-10 | 2014-07-29 | Cook Biotech Incorporated | Graft for hysterotomy closure |
WO2008109407A2 (en) * | 2007-03-02 | 2008-09-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Extracellular matrix-derived gels and related methods |
US9636438B2 (en) * | 2007-03-07 | 2017-05-02 | Coloplast A/S | Fistula plug comprising ECM |
US9427223B2 (en) * | 2007-04-09 | 2016-08-30 | Creative Surgical, Llc | Frame device |
US9283302B2 (en) * | 2011-12-16 | 2016-03-15 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
US20080279833A1 (en) * | 2007-05-10 | 2008-11-13 | Matheny Robert G | Laminate sheet articles for tissue regeneration |
US9034367B2 (en) * | 2007-05-10 | 2015-05-19 | Cormatrix Cardiovascular, Inc. | Articles for tissue regeneration with biodegradable polymer |
US20080281419A1 (en) * | 2007-05-10 | 2008-11-13 | Matheny Robert G | Breast implants and compositions of extracellular matrix |
US9066993B2 (en) * | 2007-05-10 | 2015-06-30 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
US8257434B2 (en) | 2007-12-18 | 2012-09-04 | Cormatrix Cardiovascular, Inc. | Prosthetic tissue valve |
US8679176B2 (en) | 2007-12-18 | 2014-03-25 | Cormatrix Cardiovascular, Inc | Prosthetic tissue valve |
US8858698B2 (en) * | 2008-09-05 | 2014-10-14 | Mentor Worldwide Llc | Acellular matrix glue |
US7927414B2 (en) * | 2008-09-05 | 2011-04-19 | Ethicon, Inc. | Method of manufacturing acellular matrix glue |
WO2010085449A1 (en) | 2009-01-23 | 2010-07-29 | Cook Incorporated | Vessel puncture closure device |
CA2752899A1 (en) | 2009-02-18 | 2010-08-26 | Cormatrix Cardiovascular, Inc. | Compositions and methods for preventing cardiac arrhythmia |
WO2010101780A2 (en) * | 2009-03-04 | 2010-09-10 | Peytant Solutions, Inc. | Stents modified with material comprising amnion tissue and corresponding processes |
US9511093B2 (en) * | 2009-03-23 | 2016-12-06 | The Texas A & M University System | Compositions of mesenchymal stem cells to regenerate bone |
CA2786400C (en) | 2010-01-05 | 2018-11-27 | Cell Constructs, Inc. | Biomaterials made from human hair |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8840665B2 (en) | 2010-06-11 | 2014-09-23 | Liventa Bioscience, Inc. | Method of tendon repair with amnion and chorion constructs |
US20120010708A1 (en) * | 2010-07-08 | 2012-01-12 | AFcell Medical | Amnion and chorion replacement cover and uses thereof in surgical repair of muscles |
US9421307B2 (en) | 2010-08-17 | 2016-08-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biohybrid composite scaffold |
EP2608777B1 (en) | 2010-08-24 | 2019-07-24 | The Regents of the University of California | Compositions and methods for cardiac therapy |
US10143778B2 (en) * | 2010-12-21 | 2018-12-04 | Cormatrix Cardiovascular, Inc | Cardiovascular prostheses |
US10201636B2 (en) * | 2010-12-20 | 2019-02-12 | Cormatrix Cardiovascular, Inc. | Cardiovascular prostheses |
AU2012262549B2 (en) | 2011-05-27 | 2016-02-11 | Cormatrix Cardiovascular, Inc. | Extracellular matrix material valve conduit and methods of making thereof |
US20170100514A1 (en) * | 2011-12-16 | 2017-04-13 | Cormatrix Cardiovascular, Inc. | Cardiovascular Prostheses |
US8961617B2 (en) | 2012-03-08 | 2015-02-24 | Liventa Bioscience, Inc. | Amnion and chorion constructs and uses thereof in abdominal surgery |
US9532866B2 (en) * | 2012-03-15 | 2017-01-03 | L&C Bio Co., Ltd. | Acellular dermal graft |
US9811613B2 (en) * | 2012-05-01 | 2017-11-07 | University Of Washington Through Its Center For Commercialization | Fenestration template for endovascular repair of aortic aneurysms |
US9220586B2 (en) * | 2012-09-28 | 2015-12-29 | Covidien Lp | Surgical implant and applicator |
US20150100115A1 (en) * | 2012-10-08 | 2015-04-09 | Cormatrix Cardiovascular, Inc. | Extracellular Matrix Prostheses for Treating Damaged Biological Tissue |
US20150094799A1 (en) * | 2012-10-08 | 2015-04-02 | Cormatrix Cardiovascular, Inc. | Extracellular Matrix Prostheses for Treating Damaged Biological Tissue |
US9498559B2 (en) * | 2012-10-08 | 2016-11-22 | Cormatrix Cardiovascular, Inc. | Reinforced vascular protheses |
HUE042704T2 (en) * | 2013-04-08 | 2019-07-29 | Regentys Corp | Method and composition for treating inflammatory bowel disease without colectomy |
WO2017160878A1 (en) | 2016-03-14 | 2017-09-21 | Asana Medical, Inc. | Method and composition for treating inflammatory bowel disease |
US20160053231A1 (en) * | 2013-04-10 | 2016-02-25 | Tufts University | Two and three dimensional decellularized ecm constructs and uses therefor |
CN103394126B (en) * | 2013-07-11 | 2014-12-31 | 陕西佰傲再生医学有限公司 | Cartilage repair material and preparation method thereof |
US9801910B2 (en) | 2014-03-17 | 2017-10-31 | Ethicon, Inc. | Decellularized pleural matrix |
KR102624370B1 (en) | 2014-03-21 | 2024-01-15 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix |
US10765705B2 (en) | 2014-11-24 | 2020-09-08 | Prime Merger Sub, Llc | Visco-supplement compositions, and methods of use thereof |
WO2016094106A1 (en) * | 2014-12-10 | 2016-06-16 | Cormatrix Cardiovascular, Inc. | Biocompatable annular prostheses and methods for forming same |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
CA2983464A1 (en) | 2015-04-23 | 2016-10-27 | Aortica Corporation | Devices and methods for anatomic mapping for prosthetic implants |
CN104888273B (en) * | 2015-05-14 | 2017-08-22 | 四川大学 | A kind of double-layer composite endocranium and preparation method thereof |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
EP3319552B1 (en) | 2015-07-08 | 2021-08-25 | Aortica Corporation | Devices and methods for anatomic mapping for prosthetic implants |
US9855146B2 (en) * | 2015-08-24 | 2018-01-02 | Arthrex, Inc. | Arthroscopic resurfacing techniques |
US11484401B2 (en) | 2016-02-01 | 2022-11-01 | Medos International Sarl | Tissue augmentation scaffolds for use in soft tissue fixation repair |
US11357495B2 (en) | 2016-02-01 | 2022-06-14 | Medos International Sarl | Tissue augmentation scaffolds for use with soft tissue fixation repair systems and methods |
WO2018026768A1 (en) | 2016-08-02 | 2018-02-08 | Aortica Corporation | Systems, devices, and methods for coupling a prosthetic implant to a fenestrated body |
CN107913436A (en) * | 2016-10-09 | 2018-04-17 | 刘英芹 | Act on the bone and soft tissue synchronizing regeneration derivant of disability tissue in situ |
ES2931299T3 (en) | 2017-03-02 | 2022-12-28 | Univ Pittsburgh Commonwealth Sys Higher Education | Extracellular matrix (ECM) hydrogel and soluble fraction thereof for use in the treatment of cancer |
WO2019060816A2 (en) | 2017-09-25 | 2019-03-28 | Aortica Corporation | Systems, devices, and methods for coupling a prosthetic implant to a fenestrated body |
CN108795867A (en) * | 2018-06-05 | 2018-11-13 | 华东理工大学 | The method for shifting external threedimensional model for building colon cancer cell peritonaeum |
CN109758261A (en) * | 2019-03-07 | 2019-05-17 | 上海白衣缘生物工程有限公司 | A kind of solid tendon biological sticking patch and its preparation method and application |
WO2020206228A1 (en) | 2019-04-03 | 2020-10-08 | The Secant Group, Llc | Human cell-deposited extracellular matrix coatings for textiles and fibers |
US11826490B1 (en) | 2020-12-29 | 2023-11-28 | Acell, Inc. | Extracellular matrix sheet devices with improved mechanical properties and method of making |
US11376347B1 (en) * | 2021-06-21 | 2022-07-05 | The Florida International University Board Of Trustees | Materials and methods for accelerating cardiovascular tissue regeneration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638312B2 (en) * | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2127903A (en) * | 1936-05-05 | 1938-08-23 | Davis & Geck Inc | Tube for surgical purposes and method of preparing and using the same |
US4361552A (en) * | 1980-09-26 | 1982-11-30 | Board Of Regents, The University Of Texas System | Wound dressing |
CA1340581C (en) * | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US4956178A (en) * | 1988-07-11 | 1990-09-11 | Purdue Research Foundation | Tissue graft composition |
US4902508A (en) * | 1988-07-11 | 1990-02-20 | Purdue Research Foundation | Tissue graft composition |
DK124690D0 (en) * | 1990-05-18 | 1990-05-18 | Henning Rud Andersen | FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION |
US5127903A (en) * | 1990-05-22 | 1992-07-07 | Mailot Kevin G | Device for dispensing medicaments to infants |
US5281422A (en) * | 1991-09-24 | 1994-01-25 | Purdue Research Foundation | Graft for promoting autogenous tissue growth |
US5641518A (en) * | 1992-11-13 | 1997-06-24 | Purdue Research Foundation | Method of repairing bone tissue |
US5275826A (en) * | 1992-11-13 | 1994-01-04 | Purdue Research Foundation | Fluidized intestinal submucosa and its use as an injectable tissue graft |
US5352463A (en) * | 1992-11-13 | 1994-10-04 | Badylak Steven F | Tissue graft for surgical reconstruction of a collagenous meniscus and method therefor |
US5902279A (en) | 1993-04-20 | 1999-05-11 | Advanced Cytometrix, Inc. | Aspiration needle and method |
AU7324094A (en) | 1993-07-16 | 1995-02-13 | Schering Corporation | Cell surface protein present on nk (natural killer cells) named dx1 |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5916265A (en) * | 1994-03-30 | 1999-06-29 | Hu; Jie | Method of producing a biological extracellular matrix for use as a cell seeding scaffold and implant |
JPH09512184A (en) * | 1994-04-29 | 1997-12-09 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | Improved blood contact surface utilizing endothelium on subendothelial extracellular matrix |
NZ293419A (en) | 1994-09-12 | 1998-11-25 | Advanced Tissue Sciences Inc | Stromal cell-coated heart valves, production thereof |
US6485723B1 (en) * | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
US5695998A (en) | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
US5554389A (en) * | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
DE69622548T2 (en) * | 1995-04-07 | 2003-09-18 | Purdue Research Foundation West Lafayette | TISSUE TRANSPLANT FOR BUBBLE RECONSTRUCTION |
US5733337A (en) * | 1995-04-07 | 1998-03-31 | Organogenesis, Inc. | Tissue repair fabric |
US20050026838A1 (en) * | 1995-06-05 | 2005-02-03 | Human Genome Sciences, Inc. | Fibroblast Growth Factor-13 |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
ES2208974T3 (en) * | 1996-08-23 | 2004-06-16 | Cook Biotech, Inc. | PROTESIS OF GRAFT, MATERIALS AND METHODS. |
EP0942739B1 (en) * | 1996-12-10 | 2006-04-12 | Purdue Research Foundation | Biomaterial derived from vertebrate liver tissue |
CA2267310C (en) | 1996-12-10 | 2012-09-18 | Purdue Research Foundation | Stomach submucosa derived tissue graft |
NL1004827C2 (en) * | 1996-12-18 | 1998-06-19 | Surgical Innovations Vof | Device for regulating blood circulation. |
US5993844A (en) * | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
DK1011699T3 (en) * | 1997-09-11 | 2002-03-11 | Purdue Research Foundation | Galactosidase-modified submucosal tissue |
US7452371B2 (en) * | 1999-06-02 | 2008-11-18 | Cook Incorporated | Implantable vascular device |
JP4399585B2 (en) * | 1998-06-02 | 2010-01-20 | クック インコーポレイティド | Multi-sided medical device |
MXPA00012063A (en) * | 1998-06-05 | 2003-04-22 | Organogenesis Inc | Bioengineered vascular graft support prostheses. |
US7628803B2 (en) * | 2001-02-05 | 2009-12-08 | Cook Incorporated | Implantable vascular device |
US6576618B1 (en) * | 1999-06-22 | 2003-06-10 | Research Development Foundation | Methods to enhance wound healing and enhanced wound coverage material |
JP4409803B2 (en) * | 1999-09-10 | 2010-02-03 | クック・インコーポレイテッド | Valve assembly for use in a lumen of a vessel and method for making the valve assembly |
US6440164B1 (en) * | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
US6576265B1 (en) * | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
PL211860B1 (en) | 2000-01-31 | 2012-07-31 | Cook Biotech Inc | Valve stent system |
WO2001066043A1 (en) * | 2000-03-03 | 2001-09-13 | Thorpe Patricia E | Bulbous valve and stent for treating vascular reflux |
US6962814B2 (en) * | 2000-08-16 | 2005-11-08 | Duke University | Decellularized tissue engineered constructs and tissues |
IL139708A0 (en) | 2000-11-15 | 2002-02-10 | Amiel Gilad | Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering |
US6585761B2 (en) * | 2001-03-01 | 2003-07-01 | Syde A. Taheri | Prosthetic vein valve and method |
WO2002090528A1 (en) * | 2001-05-10 | 2002-11-14 | Georgia Tech Research Corporation | Soft tissue devices and methods of use |
AU2002320189B2 (en) | 2001-06-28 | 2007-04-26 | Cook Biotech Incorporated | Graft prosthesis devices containing renal capsule collagen |
EP1476095A4 (en) | 2002-02-20 | 2007-04-25 | Francisco J Osse | Venous bi-valve |
US6716241B2 (en) * | 2002-03-05 | 2004-04-06 | John G. Wilder | Venous valve and graft combination |
US6752828B2 (en) * | 2002-04-03 | 2004-06-22 | Scimed Life Systems, Inc. | Artificial valve |
CN1713861A (en) * | 2002-05-02 | 2005-12-28 | 普渡研究基金会 | Vascularization enhanced graft constructs |
AU2003238162A1 (en) * | 2002-06-28 | 2004-01-19 | Cardio Inc | Decellularized tissue |
CA2487131C (en) * | 2002-06-28 | 2011-04-26 | Cook Incorporated | Thoracic stent graft introducer |
JP2004071560A (en) * | 2002-08-07 | 2004-03-04 | Samsung Sdi Co Ltd | Polymer electrolyte for lithium-sulfur battery and lithium-sulfur battery comprising same |
AU2003272226A1 (en) * | 2002-08-20 | 2004-03-11 | Cook Incorporated | Stent graft with improved proximal end |
AU2002951147A0 (en) * | 2002-09-02 | 2002-09-19 | Cook Incorporated | Branch grafting device and method |
WO2004022107A2 (en) | 2002-09-06 | 2004-03-18 | Cook Biotech Incorporated | Tissue graft prosthesis devices containing juvenile or small diameter submucosa |
DE10243700A1 (en) | 2002-09-20 | 2004-04-01 | Oelmühle Leer Connemann Gmbh & Co. | Method and device for producing biodiesel |
AU2003295797B2 (en) * | 2002-11-22 | 2009-01-29 | Cook Biotech, Inc. | Stent tissue graft prosthesis |
US9408731B2 (en) * | 2002-12-04 | 2016-08-09 | Cook Medical Technologies Llc | Method and device for treating aortic dissection |
EP1615595B1 (en) * | 2003-04-24 | 2009-10-21 | Cook Incorporated | Artificial valve prosthesis with improved flow dynamics |
WO2005002601A1 (en) * | 2003-06-25 | 2005-01-13 | Badylak Stephen F | Conditioned matrix compositions for tissue restoration |
US6763776B1 (en) * | 2003-06-30 | 2004-07-20 | Industrial Sales Corporation | Cleat device for a flexible line and method of using same |
AU2004270239C1 (en) | 2003-09-04 | 2011-07-07 | Cook Biotech Incorporated | Extracellular matrix composite materials, and manufacture and use thereof |
EP1863545B1 (en) * | 2005-03-19 | 2015-11-18 | Cook Biotech, Inc. | Prosthetic implants including ECM composite material |
US7939481B2 (en) * | 2007-10-31 | 2011-05-10 | Nazzaro John | Color changing bar soap |
-
2004
- 2004-09-07 AU AU2004270239A patent/AU2004270239C1/en not_active Ceased
- 2004-09-07 WO PCT/US2004/029016 patent/WO2005023321A2/en active Search and Examination
- 2004-09-07 GB GB0605898A patent/GB2423934B/en not_active Expired - Fee Related
- 2004-09-07 CA CA2536923A patent/CA2536923C/en not_active Expired - Fee Related
-
2006
- 2006-03-03 US US11/368,077 patent/US7795027B2/en active Active
-
2009
- 2009-03-06 US US12/399,635 patent/US9186435B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638312B2 (en) * | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186435B2 (en) | 2003-09-04 | 2015-11-17 | Cook Biotech, Incorporated | Extracellular matrix composite materials, and manufacture and use thereof |
US7795027B2 (en) | 2003-09-04 | 2010-09-14 | Cook Biotech Incorporated | Extracellular matrix composite materials, and manufacture and use thereof |
EP1863545B1 (en) * | 2005-03-19 | 2015-11-18 | Cook Biotech, Inc. | Prosthetic implants including ECM composite material |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
US8187619B2 (en) | 2006-10-23 | 2012-05-29 | Cook Biotech Incorporated | Enhanced compositions containing cells and extracellular matrix materials |
US8455008B2 (en) | 2006-10-23 | 2013-06-04 | Cook Biotech Incorporated | Processed ECM materials with enhanced component profiles |
US8192763B2 (en) | 2006-10-23 | 2012-06-05 | Cook Biotech Incorporated | Processed ECM materials with enhanced component profiles |
WO2008154149A2 (en) * | 2007-06-07 | 2008-12-18 | Zimmer Orthobiologics, Inc. | Tissue processing for nonimmunogenic implants |
WO2008154149A3 (en) * | 2007-06-07 | 2009-11-12 | Zimmer Orthobiologics, Inc. | Tissue processing for nonimmunogenic implants |
US9687590B2 (en) | 2007-07-03 | 2017-06-27 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
US9149562B2 (en) | 2007-07-03 | 2015-10-06 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
US10842610B2 (en) | 2007-07-03 | 2020-11-24 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
US9993326B2 (en) | 2007-07-03 | 2018-06-12 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
WO2009005596A1 (en) * | 2007-07-03 | 2009-01-08 | Histogenic Corp. | Double-structured tissue implant and a method for preparation and use thereof |
US8685107B2 (en) | 2007-07-03 | 2014-04-01 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
US9421304B2 (en) | 2007-07-03 | 2016-08-23 | Histogenics Corporation | Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant |
US9393347B2 (en) | 2007-07-03 | 2016-07-19 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
US8070827B2 (en) | 2007-07-03 | 2011-12-06 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
WO2009089110A2 (en) * | 2008-01-04 | 2009-07-16 | Boston Scientific Scimed, Inc. | Methods for repair and regeneration of bone marrow |
WO2009089110A3 (en) * | 2008-01-04 | 2010-03-18 | Boston Scientific Scimed, Inc. | Methods for repair and regeneration of bone marrow |
US8801725B2 (en) | 2008-03-10 | 2014-08-12 | Zimmer Orthobiologics, Inc. | Instruments and methods used when repairing a defect on a tissue surface |
US20100082114A1 (en) * | 2008-04-29 | 2010-04-01 | Peter Gingras | Tissue repair implant |
US8709096B2 (en) * | 2008-04-29 | 2014-04-29 | Proxy Biomedical Limited | Tissue repair implant |
US9468702B2 (en) | 2008-04-29 | 2016-10-18 | Proxy Biomedical Limited | Tissue repair implant |
US10220114B2 (en) | 2008-04-29 | 2019-03-05 | Proxy Biomedical Limited | Tissue repair implant |
EP2113263A3 (en) * | 2008-04-30 | 2010-03-17 | Aesculap AG | Implant, in particular for restoring and/or regenerating human and/or animal tissue |
WO2011028521A3 (en) * | 2009-09-02 | 2011-07-14 | Lifecell Corporation | Vascular grafts derived from acellular tissue matrices |
AU2010289856B2 (en) * | 2009-09-02 | 2015-02-12 | Lifecell Corporation | Vascular grafts derived from acellular tissue matrices |
EP2756853A3 (en) * | 2009-09-02 | 2014-12-10 | Lifecell Corporation | Vascular grafts derived from acellular tissue matrices |
US10525164B2 (en) | 2009-09-02 | 2020-01-07 | Lifecell Corporation | Vascular grafts derived from acellular tissue matrices |
US10071187B2 (en) | 2010-05-25 | 2018-09-11 | Cook Biotech Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
WO2011150055A3 (en) * | 2010-05-25 | 2012-07-12 | Cook Biotech Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
US11077231B2 (en) | 2010-05-25 | 2021-08-03 | Muffin Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
US11173231B2 (en) | 2010-05-25 | 2021-11-16 | Muffin Incorporated | Methods, substrates, and systems useful for cell seeding of medical grafts |
US8435305B2 (en) | 2010-08-31 | 2013-05-07 | Zimmer, Inc. | Osteochondral graft delivery device and uses thereof |
US9113916B2 (en) | 2010-08-31 | 2015-08-25 | Zimmer, Inc. | Drill bit for osteochondral drilling with guiding element and uses thereof |
US8753406B2 (en) | 2010-08-31 | 2014-06-17 | Zimmer Inc. | Osteochondral graft delivery device and uses thereof |
CN103263694A (en) * | 2013-05-14 | 2013-08-28 | 北京华信佳音医疗科技发展有限责任公司 | Collagen-based dura and preparation method thereof |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US11555172B2 (en) | 2014-12-02 | 2023-01-17 | Ocugen, Inc. | Cell and tissue culture container |
CN115337458A (en) * | 2022-08-16 | 2022-11-15 | 尧舜泽生物医药(南京)有限公司 | Cell matrix nerve graft for repairing peripheral nerve injury and preparation method thereof |
CN115337458B (en) * | 2022-08-16 | 2023-08-22 | 尧舜泽生物医药(南京)有限公司 | Cell matrix nerve graft for repairing peripheral nerve injury and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2536923C (en) | 2012-10-09 |
GB2423934A (en) | 2006-09-13 |
AU2004270239C1 (en) | 2011-07-07 |
AU2004270239A1 (en) | 2005-03-17 |
US20090204228A1 (en) | 2009-08-13 |
US20060147433A1 (en) | 2006-07-06 |
CA2536923A1 (en) | 2005-03-17 |
GB2423934B (en) | 2007-11-28 |
GB0605898D0 (en) | 2006-05-03 |
AU2004270239B2 (en) | 2010-12-09 |
US9186435B2 (en) | 2015-11-17 |
WO2005023321A3 (en) | 2005-12-22 |
US7795027B2 (en) | 2010-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2536923C (en) | Extracellular matrix composite materials, and manufacture and use thereof | |
US8454678B2 (en) | Prosthetic implants including ECM composite material | |
CA2452033C (en) | Graft prosthesis devices containing renal capsule collagen | |
US6652583B2 (en) | Cardiac valve replacement | |
EP1503625B1 (en) | Vascularization enhanced graft constructs | |
US7771717B2 (en) | Enhanced submucosal tissue graft constructs | |
AU2002320189A1 (en) | Graft prosthesis devices containing renal capsule collagen | |
EP3678714B1 (en) | Tissue-engineered medical device | |
Woods et al. | Improved biocompatibility of small intestinal submucosa (SIS) following conditioning by human endothelial cells | |
AU766719B2 (en) | Enhanced submucosal tissue graft constructs | |
AU2007203460B2 (en) | Graft prosthesis devices containing renal capsule collagen | |
Pingchuan Zhang et al. | Collagen biomaterials for cardiac tissue engineering applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2536923 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004270239 Country of ref document: AU Ref document number: 11368077 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2004270239 Country of ref document: AU Date of ref document: 20040907 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004270239 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0605898.6 Country of ref document: GB Ref document number: 0605898 Country of ref document: GB |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 11368077 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |